Publications by authors named "Allison Rosenthal"

Background: CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune response that frequently occurs after CAR T-cell infusion. It can cause cardiac dysfunction and circulatory collapse negatively impacting outcomes and survival.

View Article and Find Full Text PDF

Primary central nervous system lymphoma (PCNSL) is clinically challenging due to its location and small biopsy size, leading to a lack of comprehensive molecular and biologic description. We previously demonstrated that 91% of PCNSL belong to the activated B-cell-like (ABC) molecular subtype of diffuse large B-cell lymphoma (DLBCL). Here we investigated the expression of 739 cancer related genes in HIV (-) patients using NanoString digital gene expression profiling in 25 ABC-PCNSL and 43 ABC-systemic DLBCL, all tumors were EBV (-).

View Article and Find Full Text PDF

Background: Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon type of aggressive B-cell non-Hodgkin lymphoma. PMBCL shares some clinical and biologic features with nodular sclerosis classic Hodgkin lymphoma (cHL). Central nervous system (CNS) relapse is exceedingly rare in cHL.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the effectiveness of epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) by comparing it to other therapies used after at least two prior treatments, using advanced statistical methods to ensure fair comparisons.
  • - Epcoritamab showed significantly better response and overall survival rates than traditional chemoimmunotherapy (CIT) and other novel therapies, such as polatuzumab-based and tafasitamab-based regimens.
  • - However, there were no significant differences in response or survival rates when comparing epcoritamab to CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma.
View Article and Find Full Text PDF

Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is heightened in individuals with limited/localized disease before CART. This study reports on the outcomes of patients with R/R NHL and limited (<5 involved sites) disease bridged with or without radiotherapy. A multicenter retrospective review of 150 patients with R/R NHL who received CART with <5 disease sites before leukapheresis was performed.

View Article and Find Full Text PDF
Article Synopsis
  • The standard treatment for fit patients with relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by autologous stem cell transplant (ASCT), but it may not be ideal for everyone.
  • A study of 151 patients showed that while most had good responses before ASCT, those who had multiple lines of salvage chemotherapy or were diagnosed at an advanced stage faced significantly worse outcomes.
  • Median progression-free survival was 54.5 months and overall survival was 88.9 months, with no significant survival difference based on age or other characteristics, although advanced-stage relapse and multiple salvage treatments negatively affected survival rates.
View Article and Find Full Text PDF

Purpose: Low-dose total skin electron beam therapy (TSEBT) is a proven treatment for managing cutaneous T-cell lymphoma (CTCL) and Sezary syndrome with skin burden. We performed a retrospective comparison of response rates and time to progression for patients receiving low-dose TSEBT based on dose per fractionation, total dose, and stage.

Methods And Materials: One hundred and ten patients with CTCL and Sezary syndrome were treated with 135 courses of low-dose (400-1500 cGy) TSEBT or subtotal skin electron therapy at multiple centers of a single institution between August 2003 and June 2023.

View Article and Find Full Text PDF
Article Synopsis
  • * In a study of 226 older patients, the therapy achieved an 86% objective response rate and 62% complete response rate, with a median progression-free survival of 6.9 months.
  • * Results indicate that age does not significantly affect the safety and efficacy of CAR-T therapy, suggesting that older patients should not be excluded from treatment based solely on age.
View Article and Find Full Text PDF

The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy.

View Article and Find Full Text PDF
Article Synopsis
  • Total skin electron beam therapy (TSEBT) is a common treatment for cutaneous T-cell lymphoma (CTCL) but can cause unnecessary side effects; a new method called subtotal skin electron beam therapy (STSEBT) uses a shield to protect healthy skin.
  • A study reviewed 32 CTCL patients, with 7 receiving STSEBT and 25 receiving TSEBT, showing a median response rate of 96% and comparable effectiveness between the two methods after a follow-up of about 465 days.
  • The findings suggest that STSEBT offers similar treatment benefits while potentially reducing toxicity for CTCL patients with less severe disease compared to traditional TSEBT.
View Article and Find Full Text PDF

Chimeric antigen receptor T-cell therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a role for salvage chemotherapy (ST) and autologous stem cell transplant (ASCT) in certain circumstances (e.g.

View Article and Find Full Text PDF

Though survival outcomes among adolescents and young adults (AYAs) with lymphoma have improved over the last three decades, socially vulnerable populations including non-White, low-income, and publicly insured groups continue to trail behind on survival curves. These disparities, while likely the result of both biological and non-biological factors, can be largely attributed to inequities in care over the full cancer continuum. Nationally representative studies have demonstrated that from diagnosis through therapy and into long-term survivorship, socially vulnerable AYAs with lymphoma face barriers to care that impact their short and long-term survival.

View Article and Find Full Text PDF

Anti-CD19 chimeric antigen receptor T-cell therapy (CART) has revolutionized the outcomes of relapsed and/or refractory B-cell non-Hodgkin lymphoma. However, CART is still limited by its availability, toxicity, and response durability. Not all patients make it to the CART infusion phase due to disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • Mantle cell lymphoma (MCL) shows diverse clinical and biological characteristics, complicating therapy choices, especially for older patients.
  • In a study of patients aged 60 and older treated with bendamustine and rituximab, key prognostic indicators included the simplified MCL international prognostic index (s-MIPI), MCL35 score, and blastoid cytology, which correlated with survival outcomes.
  • Combining robust proliferation assays like MCL35 with cytological evaluations and MIPI could help better classify and manage the risks of older MCL patients in future clinical trials.
View Article and Find Full Text PDF

We present the case of a young woman with Hodgkin lymphoma exhibiting physiologic F-FDG uptake in brown adipose tissue and lactating breast on consecutive F-FDG PET/CT scans. Both entities are common imaging interpretation pitfalls and should be recognized in oncologic F-FDG PET/CT practice. We review the imaging features and differential diagnosis of these 2 entities and discuss the radiation safety precautions during breastfeeding.

View Article and Find Full Text PDF

Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-brain barrier disruption and endothelial activation. Defibrotide was shown to reduce endothelial cell activation in vitro and is approved in the United States for treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT), and in the European Union for severe VOD/SOS after HCT in patients aged >1 month. Defibrotide may stabilize the endothelium during CAR-T therapy and reduce the rate of CAR-T-associated neurotoxicity.

View Article and Find Full Text PDF

Majority of non-Hodgkin lymphoma (NHL) patients who achieve partial response (PR) or stable disease (SD) to CAR T-cell therapy (CAR T) on day +30 progress and only 30% achieve spontaneous complete response (CR). This study is the first to evaluate the role of consolidative radiotherapy (cRT) for residual fluorodeoxyglucose (FDG) activity on day +30 post- CAR T in NHL. We retrospectively reviewed 61 patients with NHL who received CAR T and achieved PR or SD on day +30.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack of randomized controlled trials. Clinical characteristics and outcomes of 115 patients with relapse (or progression) after ASCT are studied.

View Article and Find Full Text PDF